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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results of 
the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the British English language. 
The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 100 JIA patients (7.0% systemic, 38.0% oligoarticular, 27.0% RF negative polyarthritis, 28% 
other categories) and 100 healthy children, were enrolled at the Royal Hospital for Sick Children in Glasgow. The JAMAR 
components discriminated well healthy subjects from JIA patients. All JAMAR components revealed good psychometric 
performances. In conclusion, the British English version of the JAMAR is a valid tool for the assessment of children with 
JIA and is suitable for use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the British English parent, child/adult version 
of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) [1] in patients with juvenile idiopathic 
arthritis (JIA). The JAMAR assesses the most relevant 
parent/patient-reported outcomes in JIA, including overall 
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well-being, functional status, health-related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance and satisfaction with illness 
outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the British English language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from February 2013 
to July 2013. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle Visual Analogue Scale (VAS) 
[11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The standard English version of JAMAR was defined in 
occasion of three different consensus meetings where three 
independent professional translators agreed on a unique 
standard English translation of the first Italian draft of 
JAMAR. The three independent translators were selected 
on the basis of their native language, their age and sex. 
This standard English version was spread out through the 
PRINTO national coordinators who had agreed to partici-
pate. Reading comprehension and understanding of the 
text was tested in a probe sample of ten JIA parents and ten 
patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descriptive 
statistics and the psychometric issues [16]. In particular, we 
evaluated the following validity components: the first Likert 
assumption [mean and standard deviation (SD) equivalence]; 
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the second Likert assumption or equal items-scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of a 
scale should be linearly related to the total score that is 
90% of the items should have Pearson r ≥ 0.4); floor/ceiling 
effects (frequency of items at lower and higher extremes of 
the scales, respectively); internal consistency, measured by 
the Cronbach’s alpha, interscale correlation (the correlation 
between two scales should be lower than their reliability 
coefficients, as measured by Cronbach’s alpha); test–retest 
reliability or intra-class correlation coefficient (reproducibil-
ity of the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR sub-
scales with the six JIA core set variables, with the addition 
of the parent assessment of disease activity and pain by the 
Spearman’s correlation coefficients (r) [17] and the discri-
minant validity, which assesses whether the JAMAR dis-
criminates between the different JIA categories and healthy 
children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete British English parent and patient versions 
of the JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
In the probe technique analysis, all 123 lines were under-
stood by at least 80% of the parents (median 100%; range 
90–100%). All the 120 lines of the patient version of the 
JAMAR were understood by at least 80% of the children 
(median 100%; range 90–100%). The texts of the parent 
JAMAR and of the child JAMAR were unmodified after the 
probe technique.
Probe technique
In the probe technique analysis, all the 123 lines of the par-
ent version of the JAMAR were understood by at least 80% 
of the 10 parents tested (median 100%; range 90–100%). 
For the 120 lines of the patient version of the JAMAR, all 
the lines were understood by at least 80% of the children 
(median 100%; range 90–100%). The texts of the parent 
JAMAR and of the child JAMAR were unmodified after the 
probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 100 JIA patients and 100 healthy children (total of 
200 subjects), were enrolled at the Royal Hospital for Sick 
Children in Glasgow.
In the 100 JIA subjects, the JIA categories were 7.0% 
with systemic arthritis, 38.0% with oligoarthritis, 27.0% 
with RF negative polyarthritis, 1.0% with RF positive pol-
yarthritis, 5.0% with psoriatic arthritis, 9.0% with Enthesi-
tis related arthritis and 13.0% with undifferentiated arthri-
tis (Table 1).
A total of 177/200 (88.5%) subjects had the parent 
version of the JAMAR completed by a parent (97 from 
parents of JIA patients and 80 from parents of healthy 
children). The JAMAR was completed by 133/177 (75.1%) 
mothers and 44/177 (24.9%) fathers. The child version of 
the JAMAR was completed by 112/200 (56.0%) children 
age 6.7 or older. Also patients younger than 7 years old, 
capable to assess their personal condition and able to read 
and write, were asked to fill in the patient version of the 
questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing results section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input of null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. All 
response choices were used for the different HRQoL items, 
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Table 1  Descriptive statistics (medians, 1st 3rd quartiles or absolute frequencies and %) for the 100 JIA patients
Data related to the JAMAR refers to the 97 JIA patients and to the 80 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity; 10 = maximum activity), LOM limitation of motion, ANA Anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL Health-Related Quality of Life (total score ranges from 0 to 30), PhH Physical Health (total score ranges 
from 0 to 15), PsH Psychosocial Health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic 
(N = 7)
Oligoarthritis 
(N = 38)
RF− poly-
arthritis 
(N = 27)
RF+ poly-
arthritis 
(N = 1)
Psoriatic 
arthritis 
(N = 5)
Enthesitis 
related 
arthritis 
(N = 9)
Undifferenti-
ated arthritis 
(N = 13)
All JIA 
patients 
(N = 100)
Healthy 
(N = 100)
Female 4 (57.1%) 23 (60.5%) 22 (81.5%) 1 (100%) 3 (60%) 4 (44.4%) 8 (61.5%) 65 (65%) 53 (53%)
Age at visit 11.9 
(6.8–12.9)
9.9 (5-12.8) 11.9 
(9.9–15.8)
17.9 (17.9–
17.9)
12.8 (11.9–
13.9)
14.9 (10-
15.8)
11.9 (10.8–
12.9)
11.8 (8.8–
14.4)*
9.8 (6.1–14)*
Age at onset 7.1 (1.4–8.9) 3.2 (2.3–6.8) 5.8 (2.6–9.3) 13.2 (13.2–
13.2)
9.8 (3.4–
10.5)
9 (8.3–11.1) 4 (2-6.5) 5.6 (2.4-9)*
Disease duration 4.8 (3.1–5.5) 3.3 (1.3-7) 5.1 (2-9.5) 4.7 (4.7–4.7) 3.5 (2.9–7.5) 3.7 (1.7–4.9) 6.3 (3.2–9.3) 4.6 (1.8–7.6)
ESR 5 (1–5) 8 (5–12) 8 (5–12) 6 (6–6) 12 (10–14) 8 (8–9) 6 (4–15) 8 (5–12)
MD VAS 
(0–10 cm)
0 (0–1) 0 (0–2) 1 (0–2) 0 (0–0) 0 (0–0) 1 (0–2) 0 (0–2) 0 (0–2)
No. swollen joints 0 (0–0) 0 (0–1) 0 (0–2) 0 (0–0) 0 (0–0) 1 (0–2) 0 (0–0) 0 (0–1)
No. joints with 
pain
0 (0–0) 0 (0–1) 0 (0–2) 0 (0–0) 0 (0–0) 0 (0–2) 0 (0–1) 0 (0–1)
No. joints with 
LOM
0 (0–1) 1 (0–2) 1 (0–3) 1 (1–1) 0 (0–1) 2 (0–4) 2 (0–4) 1 (0–3)
No. active joints 0 (0–0) 0 (0–1) 1 (0–2) 0 (0–0) 0 (0–0) 1 (0–3) 0 (0–1) 0 (0-1.5)
Active systemic 
features
2 (28.6%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (2%)
ANA status 0 (0%) 3 (7.9%) 7 (25.9%) 0 (0%) 0 (0%) 0 (0%) 1 (7.7%) 11 (11%)
Uveitis 0 (0%) 7/37 (18.9%) 5 (18.5%) 0 (0%) 1 (20%) 0 (0%) 1 (7.7%) 14 (14.1%)
PF total score 1 (0–4) 1 (0–5) 3 (1–6) 2 (2–6) 5 (2–11) 2 (0–3) 2 (0–5)* 0 (0–0)#
Pain VAS 0.5 (0-3.5) 1.8 (0-3.5) 2.5 (0.5–5.5) 5.5 (0–7) 4 (3–7) 1.5 (0–4) 2.5 (0.5-5) 0 (0–0)#
Disease activity 
VAS
1.5 (0–3) 2 (0–4) 2.5 (0.5-5) 5 (0-5.5) 6 (3.5–6.5) 1.5 (0–7) 2 (0–5)
Well-being VAS 1.5 (0-3.5) 1 (0–3) 3 (1–5) 3 (0–7) 3 (1–7) 0.5 (0–4) 1.5 (0–5)
HRQoL PhH 1 (1–4) 3 (0–5) 5 (3–7) 4 (4–6) 5 (4–8) 2 (1–4) 4 (1–6)* 0 (0–0)#
HRQoL PsH 3 (0–3) 1 (0–4) 3 (2–5) 1 (0–5) 3 (2–4) 2 (0–2) 2 (0–4) 0 (0–0)#
HRQoL total 
score
4 (1–10) 4 (1–10) 8 (6–11) 5 (4–11) 9 (5–10) 4 (1–7) 6 (2–10) 0 (0–1)#
Pain/swell. in > 1 
joint
2 (28.6%) 22 (57.9%) 16/25 (64%) 3 (60%) 8 (88.9%) 8 (61.5%) 59/97 
(60.8%)
4 (5%)#
Morning stiff-
ness > 15 min
3 (42.9%) 14 (36.8%) 16/25 (64%) 3 (60%) 6 (66.7%) 2 (15.4%) 44/97 
(45.4%)
0 (0%)#
Subjective remis-
sion
4 (57.1%) 25 (65.8%) 19/25 (76%) 3 (60%) 8 (88.9%) 8 (61.5%) 67/97 
(69.1%)
In treatment 7 (100%) 25 (65.8%) 24/25 (96%) 5 (100%) 7 (77.8%) 9 (69.2%) 77/97 
(79.4%)
Reporting side 
effects
3/7 (42.9%) 5/25 (20%) 15/25 (62.5%) 4 (80%) 4/7 (57.1%) 3/9 (33.3%) 34/77 
(44.2%)
Taking medica-
tion regularly
6/7 (85.7%) 24/25 (96%) 21/24 (87.5%) 5 (100%) 6/7 (85.7%) 8/9 (88.9%) 70/77 
(90.9%)
With problems 
attending school
2/4 (50%) 4/18 (22.2%) 10/19 (52.6%) 1/2 (50%) 2/6 (33.3%) 2/7 (28.6%) 21 (37.5%) 0 (0%)#
Satisfied with dis-
ease outcome
7 (100%) 27 (71.1%) 19/25 (76%) 5 (100%) 4 (44.4%) 9 (69.2%) 71/97 
(73.2%)
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whereas a reduced number of response choices was used for 
all the PF items except for items 1, 2, 3, 4 and 5.
The mean and SD of the items within a scale were roughly 
equivalent for the PF and for the HRQoL items, except for 
HRQoL items 1 and 8 (data not shown). The median number 
of items marked as not applicable was 0% (0–0%) for the PF 
and 1% (0–3%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 79.0% (69.0–87.0%) for the PF 
items, 44.0% (32.0–48.0%) for the HRQoL PhH items, and 
54.0% (51.0–55.0%) for the HRQoL PsH items. The median 
ceiling effect was 0% (0–1.0%) for the PF items, 5.0% 
(0–5.0%) for the HRQoL PhH items, and 1.0% (1–2.0%) for 
the HRQoL PsH items. The median floor effect was 24.0% 
for the pain VAS, 27.0% for the disease activity VAS and 
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS Visual Analogue Scale, PF physical func-
tion, HRQoL Health-Related Quality of Life, PhH Physical Health, PsH Psychosocial Health, PF-LL PF-lower limbs, PF-HW PF-hand and 
wrist, PF-US PF-upper segment
Parent (N = 97/177) Child (N = 71/112)
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 79.0% 56.0%
 HRQoL PhH 44.0% 30.0%
 HRQoL PsH 54.0% 41.0%
 Pain VAS 24.0% 13.0%
 Disease activity VAS 27.0% 11.0%
 Well-being VAS 31.0% 17.0%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL PhH 5.0% 2.0%
 HRQoL PsH 1.0% 2.0%
 Pain VAS 0.0% 1.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 0.0% 1.0%
Items with equivalent item-scale correlation 87% for PF, 90% for HRQoL 87% for PF, 80% for HRQoL
Items with items-scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.87 0.86
 PF-HW 0.85 0.85
 PF-US 0.82 0.74
 HRQoL-PhH 0.88 0.86
 HRQoL-PsH 0.82 0.81
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.95 0.97
 HRQoL-PhH 0.91 0.92
 HRQoL-PsH 0.99 0.88
Spearman’s correlation with JIA core-set variables, median
 PF 0.4 0.3
 HRQoL PhH 0.5 0.4
 HRQoL PsH 0.3 0.2
 Pain VAS 0.4 0.5
 Disease activity VAS 0.4 0.4
 Well-being VAS 0.4 0.5
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31.0% for the well-being VAS. The median ceiling effect 
was 0% for the pain VAS, 0% for the disease activity VAS 
and 0% for the well-being VAS.
Equal items‑scale correlations (second Likert 
assumption)
Pearson items-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
items, with the exception of PF items 11 and 15, and for 90% 
of the HRQoL items, with the exception of item 1.
Items internal consistency (third Likert assumption)
Pearson items-scale correlations were ≥ 0.4 for 100% of 
items of the PF and 100% of items of the HRQoL.
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.87 for PF-LL, 0.85 for PF-HW, 0.82 
for PF-US. Cronbach’s alpha was 0.88 for HRQoL-PhH and 
0.82 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in eight JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after a 
median of 7 days (7–7 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC 0.95). The ICC for the HRQoL PhH 
and for the HRQoL PsH scores showed an almost perfect 
reproducibility (ICC 0.91 and 0.99, respectively).
Convergent validity
The Spearman’s correlation of the PF total score with 
the JIA core set of outcome variables ranged from 0.3 to 
0.7 (median 0.4). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.7, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged from 
0.3 to 0.7 (median 0.5), whereas for the PsH ranged from 0.2 
to 0.6 (median 0.3). The PhH showed the best correlation 
with the parent’s assessment of pain (r = 0.8, p < 0.001) and 
the PsH with the parent global assessment of well-being 
(r = 0.7, p < 0.001). The median correlations between the 
pain VAS, the well-being VAS, and the disease activity VAS 
and the physician-centred and laboratory measures were 0.4 
(range 0.3–0.5).
Discussion
The British English version of the JAMAR was cross-
culturally adapted from the original standard English ver-
sion, without performing the forward and backward trans-
lations. The PRINTO National Coordinator in UK revised 
the standard English original, adapted it to British English 
and administered it to a probe sample of ten JIA parents 
and ten patients. According to the results of the validation 
analysis, the British English parent and patient versions 
of the JAMAR possess satisfactory psychometric proper-
ties. The disease-specific components of the questionnaire 
discriminated well between patients with JIA and healthy 
controls. The PF total score and the PhH score proved 
to discriminate between the different JIA subtypes with 
children with Enthesitis related arthritis having a higher 
degree of disability and a lower quality of life.
Psychometric performances were good for all domains 
of the JAMAR and the overall internal consistency was 
good for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from weak to moderate.
The statistical performances of the child version of 
the JAMAR are very similar, although slightly poorer, to 
those obtained by the parent version, which suggests that 
children are reliable reporters of their disease and health 
status.
The JAMAR is aimed to evaluate the side effects of 
medications and school attendance, which are other 
dimensions of daily life than most of the previously used 
HRQoL-tools. This may provide useful information for 
intervention and follow-up in health care.
In conclusion, the British English version of the 
JAMAR was found to have excellent psychometric prop-
erties and it is, thus, a reliable and valid tool for the mul-
tidimensional assessment of children with JIA.
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